| [1] |
Güntekin B, Hanoğlu L, Güner D, et al. Cognitive impairment in Parkinson’s disease is reflected with gradual decrease of EEG delta responses during auditory discrimination[J/OL]. Front Psychol, 2018, 9: 170[2018-07-16]. https: //www.ncbi.nlm.nih.gov/pmc/articles/PMC5826339. DOI: 10.3389/fpsyg.2018.00170. |
| [2] |
McKeith IG, Boeve BF, Dickson DW, et al.
Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium[J]. NeurologyNeurology, 2017, 89(1): 88-100.
doi: 10.1212/WNL.0000000000004058 |
| [3] |
Camargo CHF, Tolentino ES, Bronzini A, et al.
Comparison of the use of screening tools for evaluating cognitive impairment in patients with Parkinson’s disease[J]. Dement NeuropsycholDement Neuropsychol, 2016, 10(4): 344-350.
doi: 10.1590/s1980-5764-2016dn1004015 |
| [4] |
Rizzo G, Arcuti S, Copetti M, et al.
Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis[J]. J Neurol Neurosurg PsychiatryJ Neurol Neurosurg Psychiatry, 2018, 89(4): 358-366.
doi: 10.1136/jnnp-2017-316844 |
| [5] |
Darweesh SKL, Wolters FJ, Postuma RB, et al.
Association between poor cognitive functioning and risk of incident parkinsonism: the Rotterdam study[J]. JAMA NeurolJAMA Neurol, 2017, 74(12): 1431-1438.
doi: 10.1001/jamaneurol.2017.2248 |
| [6] |
Park KW, Kim HS, Cheon SM, et al.
Dementia with Lewy bodies versus Alzheimer′s disease and Parkinson′s disease dementia: a comparison of cognitive profiles[J]. J Clin NeurolJ Clin Neurol, 2011, 7(1): 19-24.
doi: 10.3988/jcn.2011.7.1.19 |
| [7] |
Diner I, Dooyema J, Gearing M, et al.
Generation of clickable Pittsburgh compound B for the detection and capture of β-amyloid in Alzheimer′s disease brain[J]. Bioconjug ChemBioconjug Chem, 2017, 28(10): 2627-2637.
doi: 10.1021/acs.bioconjchem.7b00500 |
| [8] |
Lewczuk P, Riederer P, O'Bryant SE, et al.
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry[J]. World J Biol PsychiatryWorld J Biol Psychiatry, 2018, 19(4): 244-328.
doi: 10.1080/15622975.2017.1375556 |
| [9] |
Johnson KA, Gregas M, Becker JA, et al.
Imaging of amyloid burden and distribution in cerebral amyloid angiopathy[J]. Ann NeurolAnn Neurol, 2007, 62(3): 229-234.
doi: 10.1002/ana.21164 |
| [10] |
Ballard C, Ziabreva I, Perry R, et al.
Differences in neuropathologic characteristics across the Lewy body dementia spectrum[J]. NeurologyNeurology, 2006, 67(11): 1931-1934.
doi: 10.1212/01.wnl.0000249130.63615.cc |
| [11] |
Polivka J, Polivka J Jr, Krakorova K, et al.
Current status of biomarker research in neurology[J]. EPMA JEPMA J, 2016, 7(1): 14-.
doi: 10.1186/s13167-016-0063-5 |
| [12] |
Fodero-Tavoletti MT, Smith DP, McLean CA, et al.
In vitro characterization of Pittsburgh compound-B binding to Lewy bodies[J]. J NeurosciJ Neurosci, 2007, 27(39): 10365-10371.
doi: 10.1523/JNEUROSCI.0630-07.2007 |
| [13] |
Parnetti L, Tiraboschi P, Lanari A, et al.
Cerebrospinal fluid biomarkers in Parkinson′s disease with dementia and dementia with Lewy bodies[J]. Biol PsychiatryBiol Psychiatry, 2008, 64(10): 850-855.
doi: 10.1016/j.biopsych.2008.02.016 |
| [14] |
Bibl M, Mollenhauer B, Esselmann H, et al.
CSF amyloid-β-peptides in Alzheimer′s disease, dementia with Lewy Bodies and Parkinson's disease dementia[J]. BrainBrain, 2006, 129(5): 1177-1187.
doi: 10.1093/brain/awl063 |
| [15] |
Vranová HP, Hényková E, Kaiserová M, et al.
Tau protein, beta-amyloid1-42 and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia[J]. J Neurol SciJ Neurol Sci, 2014, 343(1/2): 120-124.
doi: 10.1016/j.jns.2014.05.052 |
| [16] |
Lidström AM, Hesse C, Rosengren L, et al.
Normal levels of clusterin in cerebrospinal fluid in Alzheimer's disease, and no change after acute ischemic stroke[J]. J Alzheimers DisJ Alzheimers Dis, 2001, 3(5): 435-442.
doi: 10.3233/JAD-2001-3501 |
| [17] |
Sasaki K, Doh-ura K, Wakisaka Y, et al. Clusterin/apolipoprotein J is associated with cortical Lewy bodies: immunohistochemical study in cases with α-synucleinopathies[J]. Acta Neuropathol, 2002, 104(3): 225−230. DOI: 10.1007/s00401−002−0546−4. |
| [18] |
Yu JT, Tan L.
The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy[J]. Mol NeurobiolMol Neurobiol, 2012, 45(2): 314-326.
doi: 10.1007/s12035-012-8237-1 |
| [19] |
Xing YY, Yu JT, Cui WZ, et al.
Blood clusterin levels, rs9331888 polymorphism, and the risk of Alzheimer's disease[J]. J Alzheimers DisJ Alzheimers Dis, 2012, 29(3): 515-519.
doi: 10.3233/JAD-2011-111844 |
| [20] |
Maarouf CL, Beach TG, Adler CH, et al.
Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson′s disease subjects[J]. Neurol ResNeurol Res, 2012, 34(7): 669-676.
doi: 10.1179/1743132812Y.0000000063 |
| [21] |
Přikrylová Vranová H, Mareš J, Hluštík P, et al.
Tau protein and beta-amyloid1-42 CSF levels in different phenotypes of Parkinson′s disease[J]. J Neural TransmJ Neural Transm, 2012, 119(3): 353-362.
doi: 10.1007/s00702-011-0708-4 |